Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of Japan
Taku Tsuzuki, CTO, and Yosuke Ozawa, CEO of Epistra Inc. (headquartered in Tokyo), contributed an article titled “Accelerating Drug Development with AI-Robot-Driven Approaches” to Pharmacia, the journal of the Pharmaceutical Society of Japan (a public interest incorporated association), Vol. 62 No. 7 (published July 1, 2026, pp. 670–672). The article appears as part of the issue’s special feature, “Frontiers in Robotics and Automation.”
About the Special Feature
Pharmacia is a monthly journal published by the Pharmaceutical Society of Japan. Vol. 62 No. 7 (published July 1, 2026) carries the special feature theme “Frontiers in Robotics and Automation,” covering trends in the use of robotics and automation in research and manufacturing settings.
About the Article
In the article, Tsuzuki and Ozawa present the concept of “AI-robot-driven drug development,” which combines large-scale generation of high-quality data by robots with AI-driven experimental design, addressing the “high-dimensional, high-noise, high-cost” challenges facing new drug development. Robots reduce variability in experimental operations to generate highly reproducible data, and AI then uses that data to derive the next experimental conditions from a high-dimensional search space. The AI component is provided by Epistra’s experimental condition optimization AI, “Epistra Accelerate.” This approach has already delivered results in a joint case study with Astellas Pharma Inc. on NK cell therapeutics (announced March 2025).
Going forward, Tsuzuki and Ozawa believe that this “AI-robot-driven” concept will extend beyond manufacturing processes to the entire drug discovery value chain, including target discovery and drug repositioning.
Publication Details
- Journal: Pharmacia (journal of the Pharmaceutical Society of Japan)
- Issue: Vol. 62, No. 7 (published July 1, 2026), pp. 670–672
- Special feature: Frontiers in Robotics and Automation
- Authors: Taku Tsuzuki, Yosuke Ozawa (Epistra Inc.)
- DOI: https://doi.org/10.14894/faruawpsj.62.7_670
Related Articles
Cell Culture Optimization Software 'CellTune Ver.2' Launches Globally
Epistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine Seminar
On June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.
Speaking Engagement: CEO Yosuke Ozawa Presented at LiSH Seminar 'Getting Started with AI in Research'
On May 28, 2026, Epistra Inc. CEO Yosuke Ozawa spoke as a guest presenter at the LiSH Seminar 'Getting Started with AI in Research,' hosted by Leave a Nest Co., Ltd.